A pooled analysis of tirzepatide, currently the only GIP/GLP-1 receptor agonist, in 4036 participants regardless of diabetes status, for a treatment duration of 12 to 72 weeks, showed a significant weight loss of mean difference of 7.7 kg (8.1%), 11.6 kg (11.9%), and 11.8 kg (12.4%) compared to placebo for doses of 5, 10, and 15 mg, respectively
Occasional brief light exposure during dose preparation is unavoidable and inconsequential
371 In a study examining the effects of GLP-1RA on osteoporosis induced by ovariectomy in aged rats, administering exendin-4 for 16 weeks prevented deterioration of the trabecular microarchitecture and increased bone strength
After 48 weeks, 36%-48% of subjects receiving 8 mg and 12 mg doses achieved 25% weight reduction, with no participants in the placebo group reaching this level
This paradoxical scenario highlights the complexity of GIP receptor pharmacology
Sakshi says: This really makes my skin bright and glowing Nafisa says: After using it for a good few days, I started to see the difference- pores get reduced, skin is radiant, smooth, and hydrated